NCT01248884 - Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) | Biotech Hunter

Enrollment

721

Participants

Timeline

Start Date

December 9, 2010

Primary Completion Date

January 5, 2012

Study Completion Date

January 5, 2012

Conditions

TetanusPoliomyelitisHepatitis BHaemophilus Influenzae Type bAcellular PertussisDiphtheria

Interventions

BIOLOGICAL

Infanrix hexa™

3 doses, intramuscular into left thigh

BIOLOGICAL

Prevenar 13®

3 co-administered doses, intramuscular into right thigh

BIOLOGICAL

GSK217744

3 doses, intramuscular into left thigh

Trial Locations (16)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

60100

GSK Investigational Site, Seinäjoki

67100

GSK Investigational Site, Kokkola

70210

GSK Investigational Site, Kuopio

90220

GSK Investigational Site, Oulu

Unknown

GSK Investigational Site, Santo Domingo

GSK Investigational Site, Santo Domingo, Distrito Nacional

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa